Skip to main content

02 · Clinical Findings

GLP-1 RAs Tied to Lower Kidney Failure Risk in Patients With Obesity, CKD

Pharmacy Times1 min read

Over five years, a retrospective study linked GLP-1 drug use to fewer end-stage kidney outcomes in adults with CKD and obesity who did not have diabetes.

Image from the article by Pharmacy Times: GLP-1 RAs Tied to Lower Kidney Failure Risk in Patients With Obesity, CKD
Image: Pharmacy Times

GLP-1 drug use was linked to fewer end-stage kidney outcomes over five years in adults with CKD and obesity who did not have diabetes.

In a retrospective study with 34,980 patients per group, kidney failure, dialysis or transplantation occurred in 3.3% of treated patients versus 6.0% of controls.

The findings show an association, not causation. Missing kidney health data and differences in access to care may help explain the gap.

DisclaimerEducational news and research awareness content. Not medical advice.Read full disclaimer ▾

This page shares third-party news coverage, official research listings, and public clinical updates for educational awareness only. Catalyst does not present this information as medical advice, treatment guidance, or a claim of safety, efficacy, or approval.

Related context

How this story connects across the peptide landscape.